Stamford, CT -- (SBWIRE) -- 12/21/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Sarepta Therapeutics Inc (NASDAQ:SRPT), Ion Geophysical Corp (NYSE:IO), TransAtlantic Petroleum Ltd (NYSEMKT:TAT), Exelixis, Inc. (NASDAQ:EXEL)
Sarepta Therapeutics Inc (NASDAQ:SRPT) opened the session at $18.55, trading in a range of $18.47 - $19.71. The stock showed a positive performance of +5.90% in the last trading session from its previous close of $18.46 and closed at $19.55. The stock traded on a volume of 2.92 million shares and the average volume of the stock remained 3.92 million shares. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus.
For How Long SRPT will Fight for Profitability? Read This Trend Analysis report
Ion Geophysical Corp (NYSE:IO) traded 2.52 million shares in the last business day while the average volume of the stock remained 2.10 million shares. The stock showed a negative movement of -0.93% to end at $3.19. The 52 week range of the stock remained $2.81 - $7.70. ION Geophysical Corporation provides planning and seismic processing services, software, and acquisition equipment to the energy industry worldwide. Its Solutions segment provides seismic data processing services for marine and land environments, reservoir solutions, onboard processing and quality control, and seismic data libraries, as well as services to manage the seismic process that comprise survey planning and design, data acquisition and management, pre-processing, and final subsurface imaging. The company?s Systems segment offers DigiSTREAMER system, a towed streamer; redeployable ocean bottom cable seismic data acquisition systems; shipboard recorders; DigiCOURSE, a marine streamer positioning system.
Has IO Found The Bottom And Ready To Gain Momentum? Find Out Here
TransAtlantic Petroleum Ltd (NYSEMKT:TAT) reported 2.65 million shares were exchanged during the last trade, while the average volume is about 330,871 shares. The stock escalated +50.66% and finished the day at $1.10. The beta of the stock is recorded at 1.76. TransAtlantic Petroleum Ltd., an international energy company, engages in the acquisition, exploration, development, and production of oil and natural gas. As of May 15, 2013, the company held interests in approximately 3.9 million net onshore acres of developed and undeveloped oil and natural gas properties in Turkey and Bulgaria. TransAtlantic Petroleum Ltd. was founded in 1985 and is based in Addison, Texas.
For How Long TAT’s Gloss will Attract Investors? Find out via this report
Exelixis, Inc. (NASDAQ:EXEL) shares rose, +1.03 percent from its previous close of $5.80 to close at $5.86. Traded with volume of 3.10 million shares in the prior session and the average volume of the stock remained 1.41 million shares. Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer.
Why Should Investors Buy EXEL After The Recent Gain? Just Go Here and Find Out
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)